Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy + nimotuzumab vs radiotherapy alone in platinum-ineligible locally advanced head and neck squamous cell carcinoma
ChiCTR2500114545Phase 3Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: 2-year progression-free survival (PFS) rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500114545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114545.